Effects of eicosapentaenoic acid and docosahexaenoic acid on lipoproteins in hypertriglyceridemia

Current Opinion in Endocrinology, Diabetes, and Obesity
Amish A Patel, Matthew J Budoff

Abstract

The treatment of hypertriglyceridemia (HTG) with ω-3 fatty acid preparations adds a novel therapy to reduce cardiovascular disease. This review examines the effects of eicosapentaenoic acid (EPA) and docosahexaenoic acid on lipoproteins and the cardioprotective effects in HTG. The evidence that ω-3 fatty acid therapy at prescription strength is effective and safe at lowering triglyceride levels is growing. Although EPA/docosahexaenoic acid formulations did lower triglyceride levels, an increase in low-density lipoproteins was observed and outcome data were mixed. More recent trials have shown that decreased levels of low-density lipoprotein can be achieved with EPA preparations. Although the cardiovascular outcomes data are not fully available, meta-analysis of available data reports protection against vascular disease. The addition of ω-3 fatty acid treatment should be considered in patients with severe HTG as well as high-risk patients for atherosclerotic disease. Emerging data are supportive, but long-term outcome studies are still underway.

References

Jan 1, 1992·Human Mutation·H H HobbsJ L Goldstein
Dec 29, 1998·Journal of Cardiovascular Risk·W S HarrisK Osmundsen
Feb 18, 2003·Arteriosclerosis, Thrombosis, and Vascular Biology·Penny M Kris-EthertonUNKNOWN AHA Nutrition Committee. American Heart Association
Nov 19, 2003·Regulatory Toxicology and Pharmacology : RTP·Kirpal S Sidhu
Jan 18, 2005·Journal of the American College of Cardiology·Rakesh S BirjmohunErik S G Stroes
Mar 21, 2007·The American Journal of Cardiology·John R Guyton, Harold E Bays
Mar 21, 2007·The American Journal of Cardiology·Michael H DavidsonTerry A Jacobson
Apr 3, 2007·Lancet·Mitsuhiro YokoyamaUNKNOWN Japan EPA lipid intervention study (JELIS) Investigators
Dec 28, 2007·Atherosclerosis·William S HarrisErnst J Schaefer
Jan 30, 2008·Circulation·H Robert Superko, Spencer King
Jun 11, 2008·The American Journal of Clinical Nutrition·Terry A Jacobson
Sep 23, 2009·Current Opinion in Lipidology·Nils EwaldHans-Ulrich Kloer
Jan 21, 2011·The American Journal of Cardiology·Jennifer B ChristianKimberly A Lowe
Apr 20, 2011·Circulation·Michael MillerUNKNOWN Council on the Kidney in Cardiovascular Disease
Jun 13, 2012·The New England Journal of Medicine·Jackie BoschSalim Yusuf
Nov 1, 2012·Circulation. Cardiovascular Quality and Outcomes·Sradha KotwalBruce Neal
May 10, 2013·The New England Journal of Medicine·UNKNOWN Risk and Prevention Study Collaborative GroupRoberto Marchioli
May 25, 2013·Expert Opinion on Pharmacotherapy·Christie M BallantyneParesh N Soni
Nov 1, 2013·Journal of Clinical Gastroenterology·John SchererDhiraj Yadav

❮ Previous
Next ❯

Software Mentioned

EpaNova
ANCHOR

Related Concepts

Related Feeds

Carotid Artery Diseases

Carotid artery disease is a group of pathological conditions of the carotid artery. Discover the latest research on carotid artery disease here.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.